Celltrion said Wednesday it gained a approval from South Korean regulators to launch its autoimmune disease drug Remsima SC at home, reported Pulse.
According to the news source, Remsima SC is the world's first subcutaneous biosimilar of Johnson & Johnson's Remicade.
Celltrion received marketing authorization for the drug in Europe late last year, and its distribution and marketing unit Celltrion Healthcare has already started selling it directly in Germany.
The drugmaker said Remsima SC has been approved by Korea's Ministry of Food and Drug Safety for the treatment of rheumatoid arthritis, and that it plans to expand the indication to include inflammatory bowel disease.
To read more NewsPoints articles, click here.